Figure 1.
![Figure 1. Nonmyeloablative ex vivo T-cell depleted (TCD) peripheral blood stem cell transplantation (PBSCT) and delayed donor lymphocyte infusion (DLI) for hematologic malignancy. . / This schematic representation of a nonmyeloablative conditioning regimen (cyclophosphamide ± fludarabine, anti-CD2 monoclonal antibody [MEDI-507], and thymic irradiation) shows the induction of mixed lymphohematopoietic chimerism followed by delayed DLI to convert the chimerism to full donor, thereby capturing a potent graft-versus-leukemia (GVL) effect while minimizing graft-versus-host disease (GVHD). The graph from one patient shows “split lineage” chimerism and conversion of T-cell chimerism following DLI. BMT, bone marrow transplantation.](https://ash.silverchair-cdn.com/ash/content_public/journal/hematology/2005/1/10.1182_asheducation-2005.1.390/2/spitzer_fig1.jpeg?Expires=1724231875&Signature=2IXbcHhV~b2r7kKQstBHwTsDPpa9ffSOmoVzTeNyKuZUs9Vy-yEc~GhmFZ9XGLWTjRQU47N9~SsCQXsu9lDrSJZ67obdY7u-dY19j~BFtC67PopaAWXz5KONKZUg9PEYb~qeKpAEoY-tEUzC6FGOsV0xCJezl5dOkZR6-7ZPSldAsjo3smMKz1An3-Bf6DDVt9S9xhEpB3Lw5VM7xuBlaogrVSmsWBFMYZHocm1xD8g0Drxljr9vtIFm3eLtxzY2O70QGdI3w-V5~jZFMVjb9HZBJplQZ-J~da12XqeqZeOyRwjGadbaffDjyq2Jff-CqZ5RB2tgOulOYFjtxkMSFA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Nonmyeloablative ex vivo T-cell depleted (TCD) peripheral blood stem cell transplantation (PBSCT) and delayed donor lymphocyte infusion (DLI) for hematologic malignancy.
This schematic representation of a nonmyeloablative conditioning regimen (cyclophosphamide ± fludarabine, anti-CD2 monoclonal antibody [MEDI-507], and thymic irradiation) shows the induction of mixed lymphohematopoietic chimerism followed by delayed DLI to convert the chimerism to full donor, thereby capturing a potent graft-versus-leukemia (GVL) effect while minimizing graft-versus-host disease (GVHD). The graph from one patient shows “split lineage” chimerism and conversion of T-cell chimerism following DLI. BMT, bone marrow transplantation.
